CODE BIOTHERAPEUTICS
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
CODE BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Life Science
Founded:
2020-01-01
Address:
Hatfield, Pennsylvania, United States
Country:
United States
Website Url:
http://www.codebiotx.com
Total Employee:
11+
Status:
Active
Contact:
215-996-3006
Total Funding:
85 M USD
Similar Organizations
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Board_member
Board_member
2021-04-01
Board_member
Board_member
Board_member
2021-04-01
Board_member
Board_member
2021-04-01
Board_member
2021-04-01
Current Employees Featured
Erin Brubaker COO @ Code Biotherapeutics
COO
2021-11-01
Brian McVeigh Chairman, Chief Executive Officer, and Co-Founder @ Code Biotherapeutics
Chairman, Chief Executive Officer, and Co-Founder
Robert Getts Chief Technology Officer and Co-Founder @ Code Biotherapeutics
Chief Technology Officer and Co-Founder
Lauren Kaskiel Chief Business Officer @ Code Biotherapeutics
Chief Business Officer
Lori Getts VP Preclinical and Process Development; Co-Founder @ Code Biotherapeutics
VP Preclinical and Process Development; Co-Founder
2021-03-01
Founder
Investors List
UPMC Enterprises
UPMC Enterprises investment in Series A - Code Biotherapeutics
Amgen Ventures
Amgen Ventures investment in Series A - Code Biotherapeutics
CureDuchenne Ventures
CureDuchenne Ventures investment in Series A - Code Biotherapeutics
New Enterprise Associates
New Enterprise Associates investment in Series A - Code Biotherapeutics
4BIO Capital
4BIO Capital investment in Series A - Code Biotherapeutics
UCB Ventures
UCB Ventures investment in Series A - Code Biotherapeutics
Takeda Ventures
Takeda Ventures investment in Series A - Code Biotherapeutics
JDRF T1D Fund
JDRF T1D Fund investment in Series A - Code Biotherapeutics
Northpond Ventures
Northpond Ventures investment in Series A - Code Biotherapeutics
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Code Biotherapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-02 | Code Biotherapeutics Appoints Erin Brubaker as Chief Operating Officer |
Official Site Inspections
http://www.codebiotx.com Semrush global rank: 7.76 M Semrush visits lastest month: 437
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Code Biotherapeutics"
Leadership | Code Biotherapeutics | United States - Code Bio Live …
At SwanBio, Latha led the organization’s lead candidate from the earliest preclinical stage through IND. Previously, Latha served as a Director of Translational Sciences at the Center for …See details»
Genetic Medicine | Code Biotherapeutics | United States
Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related …See details»
Code Biotherapeutics - Crunchbase Company Profile
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life …See details»
Code Bio Company Profile | Management and Employees List
Smith@codebiotx.com: Code Bio Top Competitors. Company Employees Revenue Top technologies; Transposagen Biopharmaceuticals. 13: $3.6 M: Jaguar Gene Therapy. 33: $6.3 …See details»
Org Chart Code Biotherapeutics - The Official Board
For each of our 1,280,684 listed executives, discover their exact roles and their biographies.See details»
Code Biotherapeutics, Inc. - BIO International Convention | BIO
Jun 6, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ...See details»
Code Biotherapeutics - VentureRadar
"Code Bio leverages its novel non-viral multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based delivery …See details»
Code Biotherapeutics - workinbiotech.com
Code Biotherapeutics is using non-viral approaches to develop targeted delivery of genetic medicines. To rescue defects in genetic diseases DNA gene therapies can be employed, but …See details»
code-biotherapeutics
The company is advancing an internal pipeline of therapies focused on serious and life-threatening diseases while also developing multiple collaborative partnerships to take forward …See details»
Code Bio - Overview, News & Similar companies | ZoomInfo.com
Nov 13, 2022 Code Bio contact info: Phone number: (215) 996-3006 Website: www.codebiotx.com What does Code Bio do? Code Bio founded in 2020, for patients suffering …See details»
Code Bio 2025 Company Profile: Valuation, Funding & Investors
Code Bio General Information Description. Developer of a non-viral gene therapy designed to treat serious and life-threatening genetic diseases. The company's therapy is leveraging a …See details»
About Us | Code Biotherapeutics | United States - Code Bio Live Site
Code Bio is led by seasoned leaders with expertise in business, biotechnology and nanotechnology, and is building an internal pipeline focused on select rare disease programs …See details»
Code Biotherapeutics (USA) Funding: $85M
Jan 22, 2025 Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene...See details»
News and Press - JDRF T1D Fund
Jun 7, 2022 For more information, visit www.codebiotx.com. About Northpond Ventures. Northpond Ventures is a multi-billion-dollar science-driven venture capital firm based in …See details»
Code Biotherapeutics - Company Profile - Tracxn
Feb 7, 2025 Code Biotherapeutics - Developer of gene therapies for rare diseases. Raised a total funding of $85M over 2 rounds from 12 investors. Founded by Brian P McVeigh and …See details»
News: Latest News - Code Bio Live Site
Dec 2, 2021 The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and …See details»
News: Latest News - Code Bio Live Site
Apr 20, 2021 For more information, visit www.codebiotx.com. About 4BIO Capital 4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s …See details»
Code Biotherapeutics @codebiotx - Twitter Profile - Sotwe
CodeBioTx's tweet video. 0. 2. 0. 0. 71. Share Download Video. Code Biotherapeutics @CodeBioTx. about 1 year ago. Code Bio recently hosted a #fooddrive in collaboration with …See details»
News: Latest News - Code Bio Live Site
Jun 7, 2022 The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and …See details»
Pipeline | Code Biotherapeutics | United States - Code Bio Live Site
Duchenne Muscular Dystrophy Program . Code Bio’s first gene therapy discovery program is designed to treat Duchenne Muscular Dystrophy (DMD), a debilitating genetic disorder …See details»